

Program

Hall, Knowledge Capital Congrès Convention Center, B2F, North Building, Grand Front Osaka

Sunday, October 29, 2017

8:30-9:30 General scientific session 1

Cell biology

Moderators: Mitsutoshi Nakada, Japan
Jianhong Zhu, China

GS1-01	Inhibition of homologous recombination resensitizes temozolomide-resistant glioma cells to temozolomide	Shigeo Ohba
GS1-02	Preventing relapse in GBM by targeting residual resistant cells captured from preclinical orthotopic mouse model by inhibiting SETMAR mediated NHEJ repair pathway	Shilpee Dutt
GS1-03	Human glioma stem-like cells induce malignant transformation of bone marrow mesenchymal stem cells by activating TERT expression	Jun Dong
GS1-04	Regulation of bioenergetics through dual inhibition of aldehyde dehydrogenase and mitochondrial complex I suppresses glioblastoma tumorspheres	Seok-Gu Kang
GS1-05	LRRC4 reversed by miR-101 mediated the interaction between GBM cells and Tumor infiltrated CD4+CCR4+ T cells by cytokines	Peiyao Li
GS1-06	Arg Kinase mediates CXCL12/CXCR4-induced invadopodia formation and invasion in mesenchymal subtype GBM	Long Hai

9:30-10:30 General scientific session 2

Surgery

Moderators: Koji Yoshimoto, Japan
Shin Jung, Korea

GS2-01	Patient-specific resection strategy of glioblastoma multiforme: choice based on a preoperative scoring scale	Haihui Jiang
GS2-02	Reorganization of Cerebro-cerebellar Circuit in Dominant Hemispheric Glioma Patients: A New Insight in Understanding Linguistic Plasticity	Nan Zhang
GS2-03	Awake surgery aimed for preserving social cognitive ability: Analysis about its usefulness and associated white matter network	Riho Nakajima
GS2-04	Navigated Transcranial Magnetic Stimulation (nTMS) Applied in Brain Function Research and Glioma Resection in Brain Eloquent Areas	Xuejun YANG
GS2-05	Survival benefit of lobectomy for primary glioblastomas in non-eloquent region: gross-total resection versus supratotal resection	Jong Hee Chang
GS2-06	Maximal and safe resection of glioblastoma provided by awake craniotomy	Masashi Kinoshita

10:30-12:00 Symposium 1

Lower grade glioma 1

 Moderators: Akitake Mukasa, Japan
 Dong-Sup Chung, Korea

SY1-01	The role of chemotherapy in lower grade glioma (LrGG) after the new WHO classification	Susan Chang
SY1-02	Grade II and III astrocytoma: the current state	Martin van den Bent
SY1-03	Adult IDH Wild-type Lower-grade Gliomas Should Be Further Stratified	Abudumijiti AIBAIDULA
SY1-04	NCT02209428: Does temozolomide Chemotherapy lessen Cognitive Dysfunction in Young Patients with High-risk Low Grade Gliomas?	Zeyang Li
SY1-05	Challenges in WHO2016 update-based diagnosis and treatment of anaplastic gliomas	Motoo Nagane

12:00-13:00 Lunchtime seminar 1
Sponsored by Eisai Co., Ltd.

Moderator: Toshihiro Kumabe, Japan

LS1-01	Effectiveness of awake craniotomy for glioma and epileptogenic focus resection	Nobuhiro Mikuni
---------------	--	-----------------

13:00-14:00 Symposium 2

Radiation oncology

 Moderators: Shin-ichi Miyatake, Japan
 Rakesh Jalali, India

SY2-01	Correlation of progression-free survival (PFS) with RANO criteria for response assessment in patients with primary Glioblastoma (GBM)	Narendra Kumar
SY2-02	Efficacy and safety of hypofractionated stereotactic radiosurgery for large-sized skull base meningiomas: a preliminary report on 31 patients	Hyuk-Jin Oh
SY2-03	A new and simpler prognostic index in radiosurgical treatment for patients with brain metastases	Donghwan Jeong
SY2-04	Tailor-made setting of radiation doses owing to the <i>MGMT</i> gene promoter methylation for the treatment of <i>IDH</i> -wildtype primary glioblastoma.	Toshihiko Iuchi
SY2-05	Boron neutron capture therapy (BNCT) for brain tumor	Shinji Kawabata

14:00-15:00 General scientific session 3

Immuno-oncology

 Moderators: Tetsuya Ueba, Japan
 Xiaodan Jiang, China

GS3-01	A clinical study of VEGFR1 / 2 peptide vaccine in patients with neurofibromatosis type 2	Masahiro Toda
GS3-02	A novel WT1 peptide vaccination for newly diagnosed malignant gliomas	Yu Kawanishi

GS3-03	Combination therapy with anti-PD-1 antibody and temozolomide contributes to eradication of murine glioblastoma	Seok-Gu Kang
GS3-04	Clinical Trial of Peptide Vaccination for Patients with Malignant Glioma	Ryogo Kikuchi
GS3-05	Synergistic effect of memory T cell modulation in dendritic cell-based immunotherapy	Yohei Mineharu
GS3-06	Significance of preoperative neutrophil to lymphocyte ratio on predicting of newly diagnosed glioma grade	Young Il Kim

15:00-16:00 Symposium 3
Sponsored by Chugai Pharmaceutical Co., Ltd.

Immuno-oncology

Moderator: Naoya Hashimoto, Japan

SY3-01	Peptide vaccination for malignant gliomas	Naoya Hashimoto
SY3-02	Challenges in Immunotherapy for Brain Tumors	Hideho Okada

16:00-17:00 Rapid reports 1
Biomarker and genetics

Moderators: Masayuki Kanamori, Japan
Yeon Soo Lee, Korea

RR1-01	Clinicopathological features of H3.3 G34-mutant high-grade gliomas	Koji Yoshimoto
RR1-02	CXCL13 in cerebrospinal fluid (CSF) as a biomarker for primary central nervous system lymphoma (PCNSL)	Takashi Sasayama
RR1-03	MyD88 mutation in the elderly predicts a poor prognosis in primary CNS lymphoma: multi-institutional analysis	Shingo Takano
RR1-04	Correlation between PIK3R1Met326Ile mutation, cysteine-rich protein 61 expression and poor prognosis in glioblastoma	Kazuhiko Kurozumi
RR1-05	H3F3A and TERT promoter mutations are poor prognosticators in pediatric low-grade gliomas	Abudumijiti Aibaidula
RR1-06	Clinicopathological Analysis of Adult High-Grade Gliomas Harboring BRAF V600E Mutation	Yukitomo Ishi
RR1-07	Analysis of BRAF gene alterations and mTOR signaling pathway activation in gangliogliomas	Aanchal Kakkar
RR1-08	LIN28A, a sensitive immunohistochemical marker for embryonal tumor with multilayered rosettes (ETMR) is also positive in a subset of Atypical Teratoid/Rhabdoid Tumor (AT/RT)	Shilpa Rao
RR1-09	Proteome analysis of glioma-derived extracellular vesicles isolated from neurosurgical aspirates provide markers for disease stage and progression	Susannah Hallal
RR1-10	Analysis of selected microRNAs as a potential predictors of poor outcome in glioblastoma patients	Pavel Fadrus

17:00-18:10 Rapid reports 2

Radiology

Moderators: Yoshiki Arakawa, Japan
Shiyuang Zhao, China

RR2-01	Detection of 2-hydroxyglutarate in IDH-mutant malignant gliomas by 3-tesla magnetic resonance spectroscopy	Manabu Natsumeda
RR2-02	Terahertz reflectometry imaging for low and high grade gliomas	Jong Hee Chang
RR2-03	Non-enhancing peritumoral DWI high lesion in Glioblastoma: A novel diagnostic & specific prognostic indicator	Manish Kolakshyapati
RR2-04	Radiologic Outcomes after LINAC-based Stereotactic Radiosurgery (SRS) for Vestibular Schwannomas	J. Richeleyn M. Baclay
RR2-05	Can re-irradiation for recurrent malignant gliomas be a good option?	Wan-Soo Yoon
RR2-06	Study on the judging method of brain motor function area reorganization based on nTMS and fMRI	Kai ZHANG
RR2-07	Early Initiation of Radiotherapy is a feasible option in patients diagnosed with Gliomas: A retrospective analysis of patient in a single Institution a Tertiary Care Centre	SHALEEN AGRAWAL
RR2-08	Phase I study of intrathecal pemetrexed as salvage therapy in patients with recurrent leptomeningeal metastases from non-small cell lung cancer: a preliminary report (IPRLM,NCT03101579)	Zhenyu Pan
RR2-09	Bone metastasis predicts poor prognosis of patients with brain metastases from colorectal carcinoma post aggressive treatment	Xiaobing Jiang
RR2-10	Upfront Hypofractionated Radiotherapy vs Temozolomide followed by Hypofractionated RT in High Grade Glioma Patients with Poor Performance Status - Single Institutional Experience	POULAMI BASU
RR2-11	Treatment Result and Prognostic Factors of Brain metastasis from ovarian cancer: Retrospective analysis of 56 cases	Ho Shin Gwak

Monday, October 30, 2017

8:30-10:00 Symposium 4

Frontier in brain tumor pathology Joint Session with Japan Society of Brain Tumor Pathology

Moderators: Takashi Komori, Japan
Kazuhiko Sugiyama, Japan

SY4-01	Genomic and epigenomic characterization of meningioma	Ken Aldape
SY4-02	Tumor heterogeneity and evolution for precision therapeutics in glioblastoma	Do-Hyun Nam
SY4-03	Recent Advances in Medulloblastomas : Impact and Challenges from a Neuropathologist's Perspective	Chitra Sarkar
SY4-04	Morphological and genetic features of meningioma	Shinya Tanaka
SY4-05	Distinct molecular profile of diffuse cerebellar gliomas	Masashi Nomura

10:00-10:50 Symposium 5

Sponsored by MSD K.K.

Lower grade glioma 2, 1p19q codeleted tumor

Moderator: Keisuke Ueki, Japan

SY5-01	1p/19q codeleted glioma: time to choose between quantity and quality of life?	Martin van den Bent
SY5-02	Management of oligodendroglial tumors	Hikaru Sasaki

10:50-12:00 Symposium 6

Glioblastoma

Moderators: Zhong-ping Chen, China
Sun Il Lee, Korea
Motoo Nagane, Japan

SY6-01	Update on clinical trials for glioma	Susan Chang
SY6-02	Starting point of human glioblastoma, IDH-wildtype: Subventricular zone	Seok-Gu Kang
SY6-03	Efficacy Analysis of Depatuxizumab mafodotin (ABT-414) +/- Temozolomide (TMZ) in Patients (Pts) With EGFR Amplified, Recurrent Glioblastoma (rGBM) From a Multicenter, International Phase 1 Clinical Trial	Andrew B. Lassman
SY6-04	Microcirculation patterns in glioblastoma associates with patient prognosis	Zhongping Chen
SY6-05	External validation of a recent NRG Oncology RTOG nomogram for glioblastoma: Recognizing the importance of reliable assessment of surgical resection	Jee Suk Chang

12:00-13:00 Lunchtime seminar 2**Sponsored by Chugai Pharmaceutical Co., Ltd.**

Moderator: Yoshitaka Narita, Japan

- | | | |
|---------------|--|------------------|
| LS2-01 | Current challenges in the surgical management of malignant gliomas | Yoshiki Arakawa |
| LS2-02 | Salvage stereotactic radiotherapy for recurrent malignant glioma | Hisashi Mizowaki |

13:00-14:10 General scientific session 4**Pediatric tumor**

Moderators: Hideo Takeshima, Japan
 Chitra Sarkar, India
 Hye Lim Jung, Korea

- | | | |
|---------------|--|-------------------|
| GS4-01 | Correlation of clinical and molecular data in childhood medulloblastoma: The Taiwan experience | Tai-Tong Wong |
| GS4-02 | Necessity for histological diagnosis of tumors with bifocal lesion, diabetes insipidus, and negative tumor markers | Masayuki Kanamori |
| GS4-03 | Irradiation induced Secondary Tumors for Pediatric Central Nervous System Tumors - Experiences of Taipei VGH, Taiwan (1975-2013) | Muh-Lii Liang |
| GS4-04 | Gli3 induces neuronal differentiation in WNT- and SHH- activated medulloblastoma | Manabu Natsumeda |
| GS4-05 | Single voxel proton MR spectroscopic detection of high lipid levels and low ADC is characteristics of germinoma | Fumiyuki Yamasaki |
| GS4-06 | Cancelled | |
| GS4-07 | Targeted therapy approaches and resistance mechanisms for pediatric low-grade gliomas with activated RAF gene fusions | Payal Jain |

14:10-15:00 General scientific session 5**Midline glioma**

Moderators: Koichi Ichimura, Japan
 Tai-Tong Wong, Taiwan

- | | | |
|---------------|--|-------------------|
| GS5-01 | H3.3K27M mutation-derived novel neoantigen – characterization of the HLA-A2-binding epitope and a specific T cell receptor for development of T cell-based immunotherapy | Hideho Okada |
| GS5-02 | Novel approach for epigenetic therapy targeting EZH2 and BET bromodomain in pediatric diffuse midline gliomas with H3K27M mutant. | Rintaro Hashizume |
| GS5-03 | Association of IDH, p53 and ATRX mutations with H3K27M mutations in midline gliomas | Kavneet Kaur |
| GS5-04 | Treatment strategy of spinal intramedullary gliomas-advances and new insights | Guihuai Wang |

15:00-15:30 Special lecture

Mutant IDH1 co-operates with ATRX loss to drive the alternative lengthening of telomere (ALT) phenotype in glioma

Moderator: Yukihiro Sonoda, Japan

SL01	Mutant IDH1 co-operates with ATRX loss to drive the alternative lengthening of telomere (ALT) phenotype in glioma	Russell O. Pieper
-------------	---	-------------------

15:30-16:30 General scientific session 6

Extra-axial tumor
Moderators: Takashi Tamiya, Japan
Jong Hee Chang, Korea

GS6-01	Solitary fibrous tumor / Hemangiopericytoma: treatment results based on the 2016 World Health Organization Classification	Soo Jeong Park
GS6-02	FoxM1, a master regulator of cell cycle, can be a potential target for the malignant progression of human meningioma	Shin-Hyuk Kang
GS6-03	Clinical and Radiological Predictors of Malignant Features in Intracranial Meningiomas Cancelled	Mikhail Chernov
GS6-04	POST OPERATIVE OUTCOME OF SPHENOORBITAL MENINGIOMA: REVIEW ON VISUAL ACQUITY AND PROPTOTIC INDEX	Renindra Ananda Aman
GS6-05	Factors Affecting Recurrence Risk in Intracranial Meningioma Two Years Post-Surgery in Cipto Mangunkusumo General Hospital in 2010-2015	Mirna M Iskandar
GS6-06	Tumor immunity and extracranial metastases in intracranial solitary fibrous tumor/hemangiopericytoma.	Dai Kamamoto

16:30-17:30 Rapid reports 3

Cell biology
Moderators: Tatsuya Abe, Japan
Seok-Gu Kang, Korea

RR3-01	Notch1 is a prognostic factor that exists a distinct activation in the classical and proneural subtype of glioblastoma and regulates glioma cell survival via NF- κ B(p65) pathway.	Long Hai
RR3-02	The role of a previously unrecognized pericytes progenitor-like cell in glioma expansion and progressi	Yuping Li
RR3-03	Radiotherapy with concomitant 5-aminolevulinic acid for malignant gliomas: enhancement of delayed production of reactive oxygen species in mitochondria in glioma cells.	Junkoh Yamamoto
RR3-04	Notch1 signaling pathway promotes GICs self-renewal, invasion and tumor growth through AKT/mTOR pathway activity mediated by CXCR4/CXCL12 axis	Xuejun YANG
RR3-05	Enhancement of gap junctional activity in stem cell-based suicide gene therapy by iPS cell-derived neural stem cells	Hiroaki Kenmochi

RR3-06	A Cytosolic FUS Anchor Long Noncoding RNA LINC00470 Activates ATK and Drive Astrocytoma Tumorigenesis	Changhong Liu
RR3-07	A 3D-Engineered Conformal Implant Releases DNA Nanocomplexes for Eradicating the Post-Surgery Residual Glioblastoma	Mao Qing
RR3-08	An immunohistochemical association of VEGF and peritumoral edema in diffuse gliomas	Surendra Kumar
RR3-09	Suicide gene therapy for malignant glioma using neural stem/progenitor cells derived from human induced pluripotent stem cells	Ryota Tamura
RR3-10	Intracranial remote recurrence in IDH mutant gliomas is associated with TP53 mutations and 8q gain	Shunsuke Nakae

17:30-18:40 Rapid reports 4

Surgery

Moderators: Kazuhiko Mishima, Japan
Sun Hwan Kim, Korea

RR4-01	Endoscopic surgery for intraparenchymal and ventricular tumors	Yoshiki Arakawa
RR4-02	Cancelled	
RR4-03	Spectroscopy-guided Stereotactic Brain Biopsy: Personal Experience and Literature Review Cancelled	Mikhail Chernov
RR4-04	Cancelled	
RR4-05	Neuronavigation-guided frameless stereotactic biopsy under local anesthesia in differential diagnosis of primary center nerve system lymphoma and gliomas	Yiqun Cao
RR4-06	Microsurgical Treatment of Brainstem Gliomas	Zhengwen He
RR4-07	The application of fluorescein sodium in breast cancer brain metastasis surgery	Yong-gao Mou
RR4-08	FUNCTIONAL OUTCOME IN PRIMARY EXTRAMEDULLAR INTRADURA SPINE TUMOR OPERATED IN CIPTO MANGUNKUSUMO HOSPITAL USING SF - 36 ON 2014 - 2016	Yulius Seno Nugroho
RR4-09	Post Operative - Quality of Life Improvements in Meningioma Sphenoorbital Patients with ocular Proptosis at The Department of Neurosurgery Cipto Mangunkusumo Hospital Based on EORTC QLQ-C30 Questionnaire	Kumara Wisyesa
RR4-10	Cancelled	
RR4-11	The Effectiveness of Fluorescein Fluorescence in High Grade Glioma Resection	Danu Rolian

Tuesday, October 31, 2017

8:30-9:10 General scientific session 7

Clinical practice

Moderators: Takamitsu Fujimaki, Japan
Guihuai Wang, China

GS7-01	An Updated Nationwide Epidemiology of Primary Brain Tumors in Republic of Korea, 2013	Yun-Sik Dho
GS7-02	Current Treatment Status of Adult Brain Tumors in the Philippine General Hospital	Ranhel C De Roxas
GS7-03	Survival rates and risk factors for high-grade glioma (HGG) treated at the National Cancer Referral Hospital, Jakarta, Indonesia	Rini Andriani
GS7-04	Neuro-oncology in the South of Vietnam: an early stage of development.	Huy Minh Tran

9:10-10:50 Symposium 7

Glioma biology and genetics

Moderators: Danny T M Chan, China
Kaoru Kurisu, Japan

SY7-01	Rapid conversion of mutant IDH1 from driver to passenger in a model of human gliomagenesis.	Russell O. Pieper
SY7-02	Molecular diagnosis of gliomas	Ken Aldape
SY7-03	Genetic and epigenetic stability of oligodendrogliomas at recurrence	Akitake Mukasa
SY7-04	A simple algorithmic approach utilizing histology and immunohistochemistry for the current classification of adult Diffuse Glioma in a resource limited set-up	Shilpa Rao
SY7-05	The subgroup harboring 19q loss in Anaplastic astrocytoma showed oligodendroglial morphology and good prognosis.	Ryohei Otani
SY7-06	Surgical resection and genetic evolution in glioblastoma multiforme (GBM)	Min Ho Lee

11:00-12:10 General scientific session 8

Clinical study

Moderators: Yasuo Iwadate, Japan
Se-Hyuk Kim, Korea

GS8-01	Safety and efficacy of deatuxizumab mafodotin (ABT-414) + temozolomide (TMZ) in a Phase 2 study of Japanese patients with EGFR-amplified, recurrent glioblastoma	Yoshihiro Muragaki
GS8-02	Photodynamic therapy for malignant brain tumors using talaporfin sodium	Jiro Akimoto
GS8-03	Investigator-initiated clinical trial of eribulin in patients with recurrent glioblastoma	Masamichi Takahashi
GS8-04	Phase I trial of temozolomide plus bevacizumab for newly diagnosed high-grade gliomas in the elderly patients over 75: Interim report	Hikaru Sasaki

GS8-05	Clinical significance of salvage surgery for recurrent IDH-mutant and 1p/19q-codeleted oligodendroglial tumor	Daisuke Kuga
GS8-06	Incidental low grade gliomas: Wait and See or Surgery	Kyunggi Cho
GS8-07	A systematic review of intramedullary spinal cord ependymoma and astrocytoma	Kirsty R Hamilton

12:10-13:10 Rapid reports 5

Clinical study

Moderators: Hikaru Sasaki, Japan
Youxin Zhou, China

RR5-01	Pre-surgical work-up and surgical management of low grade tumor/benign lesion related temporal lobe epilepsy	Rui Feng
RR5-02	Application of fluorescein sodium in the operation of glioma	Yiqun Cao
RR5-03	The Prognostic Improvement of Add-on Bevacizumab for Progressive Disease during Concomitant Temozolomide and Radiation Therapy in the Patients with Glioblastoma and Anaplastic Astrocytoma	Shigeru Yamaguchi
RR5-04	Use of Bevacizumab against malignant glioma cases at Tohoku University Hospital: Initial experience with 100 cases	Ryuta Saito
RR5-05	Histological analysis of glioblastoma tissue after carmustine wafer implantation	Ichiyo Shibahara
RR5-06	Repeated short-term Bevacizumab administration for glioblastoma	Tomoo Matsutani
RR5-07	Histopathological investigation of glioblastomas resected under or after bevacizumab treatment	Ryota Tamura
RR5-08	Add-on bevacizumab can prevent early clinical deterioration and prolong survival in newly diagnosed partially resected glioblastoma patients with a poor performance status	Nobuhiro Hata
RR5-09	Detection of MGMT promoter methylation levels with MS-HRM in patients with Glioblastoma	Shinji Yamashita

Poster

Poster Room, Knowledge Capital Congrès Convention Center, B2F, North Building, Grand Front Osaka

Sunday, October 29, 2017

17:00-18:00 Poster 1

P1-01	Novel function of glioma stem cells in tumor tissue remodeling: inducing host cells malignant transformation in tumor microenvironment	Chen Yanming
P1-02	Targeting transferrin receptor delivery of temozolomide for a potential glioma stem cell-mediated therapy	Ting Sun
P1-03	Downregulation of RNF138 gene suppressed proliferation, migration, invasion by regulating epithelial-mesenchymal transition, induces apoptosis of glioma cells	Haibin Wu
P1-04	ZR30 protein inhibits the glioma by targeting MMP2, EGFR, NOTCH1 and AKT signaling from the extracellular compartment of different glioma cell subpopulations of intracranial xenografts	Yanyan Li
P1-05	SALL4 suppresses PTEN expression to promote glioma cell proliferation via PI3K/AKT signaling pathway	Youxin Zhou
P1-06	Glioblastoma stem cells induce an invasive phenotype in normal astrocytes via extracellular vesicles	Susannah Hallal
P1-07	Global microRNA analysis in cerebrospinal fluid of glioblastoma patients	Pavel Fadrus
P1-08	Intracellular cholesterol positively regulates temozolomide-induced glioblastoma cell death.	Yutaro Yamamoto
P1-09	Development and characterization of a novel cell line drives from a fast growing recurrent glioma	Youxin Zhou
P1-10	LncRNA-ZNF281 influences the proliferation, invasion, and apoptosis of glioma cells by the regulation of MMP2 and VEGF both in vitro and in vivo	Yuan Hu
P1-11	ACTC1 as an Invasion and Prognosis Marker in Glioma	Masahiko Wanibuchi
P1-12	Rapid induction of glioblastoma stem cells by soft matter	Shinya Tanaka
P1-13	Temozolomide-loaded multifunctional Fe ₃ O ₄ magnetic nanoparticles as effective theranostic agents for NIR-light-mediated cancer therapy and imaging	Won Ho Cho
P1-14	Groping for the epigenetic regulation of gliomagenesis	Daisuke Ogawa
P1-15	Bevacizumab-induced normalization of tumor vasculature in glioblastoma	Norihiko Saito
P1-16	Fibroblast growth factor 13 regulates innate and bevacizumab-induced glioma cell invasion	Tomotsugu Ichikawa
P1-17	RAMBO (rapid antiangiogenesis mediated by oncolytic virus) decreased bevacizumab-induced glioma cell invasion	Yusuke Tomita
P1-18	δ -catenin modulates bevacizumab-induced glioma invasion	Toshihiko Shimizu

P1-19	Sonodynamic therapy using 220-kHz transcranial MRI-guided focused ultrasound and 5-aminolevulinic acid on malignant glioma cells	Michiharu Yoshida
P1-20	Discovering Surface Markers of Malignant Brain Tumor Using Oncopression	Kyuha Chong
P1-21	Vincristine inhibits angiogenesis in glioblastoma under hypoxia	Kyung-Jae Park
P1-22	A radiogenomic study of glioblastoma intratumor ecology	Chao Li
P1-23	Disrupting the CD forty-seven-SIRP α axis by delivery of anti-CD forty-seven monoclonal antibody induces antitumor effects in glioma cell and glioma stem cell	Feng Li
P1-24	Novel Ad-REIC vector with the super gene expression (SGE) system (Ad-SGE-REIC) as a promising therapeutic agent for malignant glioma	Atsuhito Uneda
P1-25	Targeted enzyme/drug delivery system for glioma using iPSC-derived NSCs by virus-free HSVtk gene transfer method	Tomohiro Yamasaki
P1-26	The study of stress level for glioma patient care-givers in Hong Kong	Yuk Fong Chan
P1-27	Palliative care for malignant glioma patients in Hong Kong	Claire Ka Yee Lau
P1-28	Experience with three cases of primary central nervous system B cell lymphoma with dual or triple expression of MYC and BCL2/BCL6	Keishi Makino
P1-29	Fluorescence-guided biopsy of primary central nervous system malignant lymphoma	Kazutoshi Yokoyama
P1-30	Preclinical and clinical efficacy of entrectinib in brain metastases harboring NTRK, ROS1, or ALK gene fusions	Reiko Nishiguchi
P1-31	Disastrous transtentorial herniation by intratumoral hemorrhage of the metastatic of the hepatocellular carcinoma: A case report	Choong Hyun Kim
P1-32	Direct evidence of the relationship between brain metastases of lung cancer and white matter fibers: a fiber dissection and DTI tractography study	Xiaoliang Liu
P1-33	Gamma Knife radiosurgery for multiple (4 or more) metastatic brain tumors	Sang Ryul Lee
P1-34	Radio-sensitivity enhancement with JNK inhibitor-incorporated nanoparticles in lung carcinoma cell-bearing brain tumor mouse model	Sa-Hoe Lim
P1-35	Inhibition of c-Jun N-terminal kinase activity enhances radio-sensitivity in lung cancer-bearing subcutaneous xenograft mouse model	Shin Jung
P1-36	Extensive Osteolytic and Meningocerebral Metastasis from Squamous cell Carcinoma of the Esophagus : A Case Report	Choong Hyun Kim
P1-37	Long-term outcomes of patients with brain metastases from esophageal squamous cell carcinoma: Prognostic factor and cause of death analysis	Xiaobing Jiang
P1-38	Aggressive removal of metastatic brain tumors for maintaining patients' performance status	Akhide Kondo
P1-39	Vasculogenic mimicry in brain metastasis of lung cancer	Zhongping Chen Chen
P1-40	Prognostic factors and survival outcomes of intracranial ependymoma treated with multimodality approach	Kunhiparambath Hareesh
P1-41	Epidemiology of childhood brain tumors: a nationwide population-based study in Korea 2005-2014	Hyeon Jin Park

P1-42	Endocrine Abnormalities in Childhood Medulloblastoma Survivors	Nandini C Hazarika
P1-43	Outcome of primitive neuroectodermal tumor (CNS-PNET) - a retrospective analysis in a single institute	Yi Yen Lee
P1-44	Long-term follow-up and late complications in patients with intracranial germinoma	Naoyuki Ohe
P1-45	CBTTC: Empowering pediatric brain tumor research through collaboration	Payal Jain
P1-46	The outcome of 32 patients with conservatively treated pituitary apoplexy	Youngbeom Seo
P1-47	Role of Proton MRS in Differential Diagnosis of Suprasellar Tumors Cancelled	Mikhail Chernov
P1-48	Impact of multimodal update navigation by combined use of intraoperative 3-tesla MRI and intraoperative mobile CT on endonasal endoscopic surgery: initial experience	Masahiro Tanji
P1-50	Clinical application of collagen fleece coated with fibrin sealant for transphenoidal surgery - Alternative methods of traditional methods for CSF leakage prevention	JINMO CHO
P1-51	Pituitary apoplexy mimicking acute ischemic stroke	Jae Min Ahn
P1-52	The method of locating the keypoint in the craniotomy of retrosigmoid keyhole approach	Minfeng Sheng
P1-53	The Clinical significance of MGMT Promoter Methylation Status in Patients with Glioblastoma: A Meta-analysis	Zhiqiang LI
P1-54	Differences of Temozolomide Therapy Response after Radiochemotherapy and Surgery in Glioblastoma Multiforme; Report of Two Cases	Djohan Ardiansyah
P1-55	A case of glioblastoma mimicking benign paroxysmal positional vertigo	Jae Hyeok Heo

Monday, October 30, 2017

17:30-18:30 Poster 2

P2-01	Marked improvement of spinal dissemination and syringomyelia in a patient harboring epithelioid glioblastoma after combination treatment with BRAF mutant inhibitor and MEK inhibitor	Manabu Natsumeda
P2-02	A Phase III multi-center randomised Clinical Trial: Interferon- α combined with temozolomide compared with standard adjuvant temozolomide in newly diagnosed high-grade malignant glioma patients	Qunying Yang
P2-03	Prolonged Survival and Sustained Treatment Response in Two Recurrent Glioblastoma Patients Treated with Combined Nimotuzumab and Bevacizumab	Paul Vincent A. Opinaldo
P2-04	Efficacy and safety of metronomic procarbazine and temozolomide in the treatment of recurrent glioblastoma multiforme: a retrospective analysis	William Maish
P2-05	Adjuvant temozolomide chemotherapy for newly-diagnosed anaplastic oligodendrogliomas: preliminary results	Se-Hyuk Kim
P2-06	Analysis of molecular markers in Glioblastoma and correlation with survival pattern	Ishita Pant
P2-07	The clinical significance of cadherin-11 and fascin-1 protein expression in a newly diagnosed primary glioblastoma	Ki-Su Park
P2-08	Glial tumor with high vascular proliferation and high grade spindle cell sarcomatous differentiation : A Case Report	Saemin Kwon
P2-09	Maffucci Syndrome Complicated by Three Different Central Nervous System Tumors Sharing the Common IDH1 R132C Alterations. A Case Report and Literature Review.	Takahide Nejo
P2-10	Gene expression profiling reveals PDZ Binding Kinase as a novel biomarker in Peritumoral Brain Zone of Glioblastoma.	Kruthika B S
P2-11	SERPINA3: A biomarker associated with poor patient prognosis and tumour recurrence in glioblastoma	Vidya Prasad Nimbalkar
P2-12	Delayed toxicity of stereotactic radiotherapy in long surviving glioma patients	Tomoya Oishi
P2-13	Efficacy of the intraoperative photodynamic therapy using Photolon in patients with malignant brain tumors	Yong-Wan Kim
P2-14	Efficacy and safety of nimotuzumab in addition to radiotherapy and temozolomide for cerebral glioblastoma: a phase II multicenter clinical trial	Xiao-Jing Du
P2-15	Re-irradiation by combination of Boron Neutron Capture Therapy and IMRT for radiation-induced glioblastoma : a case report	Natsuko Kondo
P2-16	Misdiagnosis of malignant brain neoplasms as stroke: Case reports and literature review	Min Kyun Na
P2-17	Clinicopathological analysis and PET study in patients with thalamic and pontine glioma	Hirohito Yano
P2-18	Volumetric assessment of peritumoral edema : excellent tool for differential diagnosis of cerebral gliomas and solitary metastases.	Saemin Kwon

P2-19	Characteristics of time-activity curves obtained from dynamic ¹¹ C-methionine PET in common primary brain tumors	Yuichi Nomura
P2-20	Rapid progression of primary glioblastoma: Is this a true natural history?	Seon-Hwan Kim
P2-21	Usefulness of spinal MRI as screening examination for patients with intracranial glioma	Kenichiro Matsuda
P2-22	Usefulness of Thallium-201 SPECT / MRI fusion image in a qualitative diagnosis with astrocytic tumor patients	Noriyuki Nakayama
P2-23	Clinical Implication of Quantitative Radiogenomic Profile - Prediction for IDH1 mutation status	Min Ho Lee
P2-24	FMISO-PET/CT and expression of HIF-1 α and VEGF	Shinya Tokunaga
P2-25	Dissociation in the longitudinal radiological changes of GBM after postoperative radiotherapy between Gd-MRI and MET-PET	Tomohiro Kawasaki
P2-26	Accuracy and safety of frameless image-guided stereotactic intracranial biopsy technique	Sosuke Sumiyoshi
P2-27	5-Aminolevulinic Acid Fluorescence Guided Resection of Malignant Glioma: Hong Kong Experience	Sonia Yi-Pin Hsieh
P2-28	Awake craniotomy with intraoperative stimulation for resection of potentially "eloquent" glioma	Sonia Y.P Hsieh
P2-29	Usefulness of intraoperative MRI during glioma surgery with preoperative PET scans	Keisuke Miyake
P2-30	Gliosarcoma of cerebello-pontine angle : a case report	Hyuk-Jin Oh
P2-31	High-grade glial tumor with Rt. mastoid bone metastasis : A case report	Saemin Kwon
P2-32	Association of extent of resection with survival based on different judgement criteria: Is T2 better than contrast-enhancing T1	Haihui Jiang
P2-33	The changes of health-related quality of life, cognitive function and activity of daily living after 6 months of intensive treatment in high grade glioma patients in Hong Kong	Susanna SM Fook
P2-34	Risk Factors of Preoperative Seizures and Predictors of Late Postoperative Seizures in Patients with Meningioma	Chae-Yong Kim
P2-35	Descriptive Epidemiology of Meningioma Patients Undergoing Surgery: A Single-Center Study of 306 Cases	Alphadenti Harlyjoy
P2-36	A novel weighted scoring system for estimating the risk of rapid growth in untreated intracranial meningiomas	Jeong Hoon Kim
P2-37	Leptomeningeal metastasis from solid tumors: clinical features and its diagnostic implication	Zhenyu Pan
P2-38	Clinical outcomes of intracranial solitary fibrous tumor and hemangiopericytoma: Analysis according to the 2016 CNS WHO classification	Byung Sup Kim
P2-39	Mitotic count and male gender are predictors of radiological recurrence after surgical excision of meningioma	Tai Chung Lam

P2-40	Gamma knife radiosurgery for residual or recurrent intracranial hemangiopericytomas	Byung Sup Kim
P2-41	Early volumetric variations in intracranial meningioma after linear accelerator-based radiation therapy	Min Kyun Na
P2-42	Predictors of posttreatment edema in patient treated with hypofractionated stereotactic radiosurgery using CyberKnife	Sung Kwon Kim
P2-43	Seizures in Patients with Newly Diagnosed Intracranial Meningiomas may be Predictive for Invasive Tumor Growth Cancelled	Mikhail Chernov
P2-44	Rare Meningiomas with Extracranial Extension: Secondary sinonasal meningioma: A Case Report	Renindra Ananda Aman
P2-45	Recurred trigeminal neuralgia associated with petrous meningioma after Gamma Knife Surgery	JEONG-TAIK KWON
P2-46	Cranio-cervical Hemangiopericytoma - Local Recurrence and Distant Metastases	Chengde Pham
P2-47	Intracranial granular cell tumor in petroclival area	Kyoung Su Sung
P2-48	Molecular investigation of brain tumors progressing during pregnancy or postpartum period	Saeko Hayashi
P2-49	Primary spinal cord Ewing's sarcoma in a 50-year-old woman: a case report	Satoshi Takahashi
P2-50	Immunohistochemical analysis of cell adhesion molecules on central neurocytoma	Yamato Nakamura
P2-51	Clinicians View and Practice Pattern on the use of Stereotactic Radiosurgery (SRS) in Brain Metastases: A Survey among Indian Radiation Oncologists.	Kazi Manir
P2-52	Endolymphatic sac tumor metastatic to spine: Extremely rare case	EUIKYO SEO
P2-53	Impact of PCR based molecular analysis in daily diagnosis for the patient with gliomas	Kiyotaka Yokogami
P2-54	Dandy-Walker syndrome associated with syringomyelia in an adult: A case report and Discussion	Nan Zhang